{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-115921","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2025-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.232434+00:00","generated_at":"2026-05-16T16:11:46.392504+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio enters new employment agreements with CEO, CFO, and CSO","bullets":["CEO David Moss: $500,000 base salary, 50% bonus target, option for 800,000 shares.","CFO Cory Ellspermann: $275,000 base salary, 40% bonus target, option for 300,000 shares.","CSO Mark Lowdell: £300,000 base salary, up to 20% annual bonus, 18-month severance.","Severance for Moss/Ellspermann: 18 months base salary, prorated bonus, and COBRA payments.","New agreements effective November 1, 2025; all include change-of-control equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-115921","json":"https://secwatch.observer/filing/0001213900-25-115921.json","markdown":"https://secwatch.observer/filing/0001213900-25-115921.md","text":"https://secwatch.observer/filing/0001213900-25-115921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025115921/0001213900-25-115921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390025115921/ea0267546-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T16:11:46.392504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}